Jupiter Topco LLC Makes New Investment in Urogen Pharma $URGN

Jupiter Topco LLC bought a new position in Urogen Pharma (NASDAQ:URGN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 19,100 shares of the company’s stock, valued at approximately $704,000.

Other hedge funds also recently made changes to their positions in the company. Partners Capital Investment Group LLP bought a new position in Urogen Pharma in the 2nd quarter valued at approximately $566,000. California State Teachers Retirement System boosted its position in Urogen Pharma by 1,605.5% in the first quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock valued at $697,000 after buying an additional 36,478 shares in the last quarter. Rice Hall James & Associates LLC bought a new stake in shares of Urogen Pharma during the second quarter worth $11,064,000. Swiss National Bank bought a new stake in shares of Urogen Pharma during the first quarter worth $1,399,000. Finally, Deutsche Bank AG acquired a new position in shares of Urogen Pharma during the second quarter worth $1,897,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Urogen Pharma

In related news, insider Mark Schoenberg sold 60,677 shares of the firm’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $47.05, for a total transaction of $2,854,852.85. Following the completion of the transaction, the insider directly owned 59,086 shares of the company’s stock, valued at $2,779,996.30. This trade represents a 50.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 80,677 shares of company stock worth $3,604,953. 4.80% of the stock is owned by company insiders.

Urogen Pharma Stock Performance

Shares of NASDAQ URGN opened at $44.09 on Monday. Urogen Pharma has a 52-week low of $15.86 and a 52-week high of $50.81. The firm has a 50 day moving average price of $42.72 and a two-hundred day moving average price of $30.83. The stock has a market cap of $2.16 billion, a P/E ratio of -22.27 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. Analysts predict that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. The Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 price target on shares of Urogen Pharma in a research note on Wednesday, July 15th. Guggenheim boosted their price objective on Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Oppenheimer upped their target price on Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a report on Thursday, July 16th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Finally, LADENBURG THALM/SH SH started coverage on Urogen Pharma in a research note on Monday, May 11th. They set a “buy” rating and a $43.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.